Phuturdex › Diseases › Lung neoplasm
Drugs in development · updated 30 October 2026
Lung neoplasm: drugs in development
As of 30 October 2026 there are 421 active clinical trials (recruiting or ongoing, phases I–III) on 348 drugs for lung neoplasm. 208 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 208 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PembrolizumabKEYTRUDA, MK-3475 | II–III | 76 | NCT07063745 |
| CarboplatinCarboplatine, Paraplatin | II–III | 72 | NCT07063745 |
| PemetrexedAxtle®, Pemfexy® | II–III | 54 | NCT07063745 |
| CisplatinCis Platinum, Cisplatine | II–III | 40 | NCT07063745 |
| DurvalumabMEDI4736, Imfinzi® | III | 39 | NCT04092283 |
| OsimertinibAZD9291, Tagrisso | III | 31 | NCT04181060 |
| PaclitaxelTaxol, Paxlitaxel | II–III | 31 | NCT07063745 |
| AtezolizumabTecentriq, MPDL3280A | III | 29 | NCT04214262 |
| NivolumabOpdivo, ONO-4538 | II–III | 29 | NCT04929041 |
| GemcitabineGemcitabin, Gemzar | II–III | 23 | NCT05096663 |
| EtoposideAvopef®, Etopophos Preservative Free® | III | 20 | NCT04092283 |
| DocetaxelTaxotere, Beizray® | II–III | 18 | NCT06616584 |
| Bevacizumabavastin, MVASI | III | 17 | NCT04181060 |
| Nab-paclitaxelAbraxane, Nab-placlitaxel | II–III | 15 | NCT07063745 |
| IpilimumabYERVOY, ipililumab IV | II–III | 13 | NCT04929041 |
Sorted by most advanced phase and number of active trials. Showing 15 of 140 drugs.
All 348 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Non-small-cell lung carcinoma 726 drugs
- Lung small cell carcinoma 197 drugs
- Colorectal neoplasm 534 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Melanoma 352 drugs
- Triple-negative breast neoplasm 334 drugs
- Ovarian neoplasm 411 drugs
- Metastasis 493 drugs
- Neoplasm 671 drugs
- Stomach neoplasm 340 drugs
- Renal cell carcinoma 228 drugs
- Breast neoplasm 593 drugs
Broader categories
- Respiratory disease 57 drugs
- Respiratory tract neoplasm 21 drugs
- Thoracic Neoplasms 25 drugs
- Lung disease 104 drugs
- Neoplasm 671 drugs
- Carcinoma, Bronchogenic 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008175 “Lung Neoplasms”.